


Scan the QR code.
The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

Scan the QR code.
The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

In pivotal Phase 3 studies, ICO provided significant skin clearance with a favorable safety profile in patients with moderate-to-severe psoriasis (PsO; ICONIC-LEAD, ICONIC-ADVANCE 1&2) and PsO affecting high-impact sites (ICONIC-TOTAL)^{2,4}



®

PBO-Controlled Period
W0-W16



- ICO exposure (AUC_{ss})

AUC_{ss}=steady state area under the concentration-time curve

Bo

GLP-1 Exposed Participants^a
(N=31)

Efficacy analysis set (pooled data from ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD; ICONIC-TOTAL was excluded due to different enrollment criteria/endpoints). Data shown are means unless otherwise noted. *Included participants who received a first GLP-1 medication dose prior to W12. †ICO and PBO groups combined.

IGA 0/1 Response at W16

GLP-1 Exposed

Not GLP-1 Exposed

100

100



PASI 90 Response at W16

Group	95% CI
GLP-1 Exposed	0.00 to 0.10
Not GLP-1 Exposed	0.00 to 0.10



In the overall pooled population, AEs were reported in 49% (636/1296) of participants in the ICO group and 52% (295/568) in the PBO group

*Poolled data from all 4 of the ICONIC studies. Participants were counted only once for any given event, regardless of the number of times they experienced the event. AEs are coded using MedDRA version 27.0. Proportions were calculated using the crude pooling method. *included all randomized and treated participants who received a first GLP-1 medication dose prior to W12.*

Pooled data from all 4 of the ICONIC studies. ICO PK parameters were assessed for all participants exposed to ICO, including those who switched from PBO to ICO at W16 (all studies) and from ducravacitinib to ICO at W24 (ICONIC-ADVANCE 182). AUC_{0-∞} refers to the post hoc population PK predicated steady state AUC. "Yes" category includes participants who reported using GLP-1 medication during the study; "No" includes participants who did not report using GLP-1 medication during study.